01521.HK
Frontage Holdings Corporation
HKSE · Healthcare · Biotechnology · US
HKD 1.03
−2.83%Year over year
Reported trailing growth
- Revenue
- +9.9%
- EBITDA
- +37.2%
- EBIT
- +76.6%
- EPS
- +188.9%
- Free cash flow
- -45.6%
- Operating cash flow
- -7.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.8%
- EBITDA
- -8.2%
- EBIT
- -21.8%
- Net income
- -35.9%
- EPS
- -35.4%
- Free cash flow
- +29.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026